Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 11.2% during the third quarter, Holdings Channel.com reports. The fund owned 823,839 shares of the company’s stock after purchasing an additional 82,978 shares during the period. Geode Capital Management LLC’s holdings in Apogee Therapeutics were worth $48,401,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Barclays PLC lifted its holdings in shares of Apogee Therapeutics by 369.2% in the third quarter. Barclays PLC now owns 365,046 shares of the company’s stock valued at $21,443,000 after purchasing an additional 287,243 shares in the last quarter. Wellington Management Group LLP lifted its position in Apogee Therapeutics by 35.7% during the 3rd quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock worth $282,798,000 after acquiring an additional 1,267,451 shares during the last quarter. Wexford Capital LP bought a new position in Apogee Therapeutics in the 3rd quarter worth approximately $230,000. Point72 DIFC Ltd boosted its stake in Apogee Therapeutics by 14.5% during the third quarter. Point72 DIFC Ltd now owns 19,207 shares of the company’s stock worth $1,128,000 after buying an additional 2,428 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Apogee Therapeutics by 162.7% in the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock valued at $41,545,000 after acquiring an additional 438,036 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Wedbush raised their target price on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Finally, Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.71.

Apogee Therapeutics Trading Down 0.4 %

APGE stock opened at $47.50 on Tuesday. The company’s 50 day moving average is $50.60 and its 200 day moving average is $48.36. Apogee Therapeutics, Inc. has a 1-year low of $27.05 and a 1-year high of $72.29. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of -19.63 and a beta of 2.30.

Insider Buying and Selling

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $56.23, for a total transaction of $2,249,200.00. Following the transaction, the chief executive officer now owns 1,354,487 shares of the company’s stock, valued at $76,162,804.01. The trade was a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carl Dambkowski sold 6,665 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $46.07, for a total transaction of $307,056.55. Following the transaction, the insider now owns 260,798 shares of the company’s stock, valued at approximately $12,014,963.86. This represents a 2.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 94,535 shares of company stock valued at $5,133,635 over the last three months. 36.10% of the stock is owned by company insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.